Endurant Capital Management LP Immuno Gen, Inc. Transaction History

Endurant Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $331,992 - $608,652	-184,440 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $444,500 - $1.09 Million	184,440 New	184,440 $500,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $252,416 - $621,430	-64,065 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $36,120 - $47,292	-4,200 Reduced 6.15%	64,065 $607,000
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $649,882 - $829,419	68,265 New	68,265 $664,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $1.41 Million - $2.73 Million	-210,800 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $670,761 - $1.05 Million	132,300 Added 168.54%	210,800 $1.35 Million
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $423,900 - $664,895	78,500	78,500 $601,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.